Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A novel device for intracolonoscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study.

van Keulen KE, Neumann H, Schattenberg JM, van Esch AAJ, Kievit W, Spaander MCW, Siersema PD.

Endoscopy. 2018 Jul 11. doi: 10.1055/a-0632-1927. [Epub ahead of print]

PMID:
29996152
2.

Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.

Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F.

Inflamm Bowel Dis. 2018 Jun 27. doi: 10.1093/ibd/izy227. [Epub ahead of print]

PMID:
29947795
3.

[Online tool to prepare patient for colonoscopy; development and implementation of a patient-education app].

Veldhuijzen G, Klemt-Kropp M, van Esch AA.

Ned Tijdschr Geneeskd. 2018;162:D1712. Dutch.

PMID:
29350118
4.

Intelligence Assessment Instruments in Adult Prison Populations: A Systematic Review.

van Esch AYM, Denzel AD, Scherder EJA, Masthoff EDM.

Int J Offender Ther Comp Criminol. 2018 Aug;62(10):3225-3244. doi: 10.1177/0306624X17739186. Epub 2017 Dec 1.

PMID:
29192526
5.

Computer-assisted instruction before colonoscopy is as effective as nurse counselling, a clinical pilot trial.

Veldhuijzen G, Klemt-Kropp M, Noomen C, Van Esch AA, Tjwa ET, Drenth J.

Endosc Int Open. 2017 Aug;5(8):E792-E797. doi: 10.1055/s-0043-110813. Epub 2017 Aug 7.

6.

Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.

Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.

Dig Dis Sci. 2017 Nov;62(11):3117-3122. doi: 10.1007/s10620-017-4661-4. Epub 2017 Jun 30.

7.

Specific Radiological Imaging Findings in Patients With Hereditary Pancreatitis During a Long Follow-up of Disease.

van Esch AA, Drenth JP, Hermans JJ.

Pancreas. 2017 Mar;46(3):372-379. doi: 10.1097/MPA.0000000000000764.

PMID:
28129231
8.

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.

Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.

J Crohns Colitis. 2016 Nov;10(11):1287-1293. Epub 2016 Apr 19.

PMID:
27095751
9.

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

Durmus S, Lozano-Mena G, van Esch A, Wagenaar E, van Tellingen O, Schinkel AH.

Mol Pharm. 2015 Dec 7;12(12):4259-69. doi: 10.1021/acs.molpharmaceut.5b00453. Epub 2015 Oct 29.

PMID:
26474710
10.

GeneXpert TB 8: A point-of-care diagnostic pilot.

Smith P, van Esch A, Wallace M, Wood R, Bekker LG.

S Afr Med J. 2014 Aug;104(8):524. No abstract available.

PMID:
26307796
11.

The Octavius1500 2D ion chamber array and its associated phantoms: dosimetric characterization of a new prototype.

Van Esch A, Basta K, Evrard M, Ghislain M, Sergent F, Huyskens DP.

Med Phys. 2014 Sep;41(9):091708. doi: 10.1118/1.4892178.

PMID:
25186383
12.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.

Pharm Res. 2015 Jan;32(1):37-46. doi: 10.1007/s11095-014-1442-z. Epub 2014 Jun 25.

PMID:
24962512
13.

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.

Iusuf D, Hendrikx JJ, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2015 Jan 1;136(1):225-33. doi: 10.1002/ijc.28970. Epub 2014 Jun 3.

14.

Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.

Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2014 Mar;85(3):520-30. doi: 10.1124/mol.113.088823. Epub 2013 Dec 13.

15.

Optimized Varian aSi portal dosimetry: development of datasets for collective use.

Van Esch A, Huyskens DP, Hirschi L, Baltes C.

J Appl Clin Med Phys. 2013 Nov 4;14(6):4286. doi: 10.1120/jacmp.v14i6.4286.

16.

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH.

Mol Cancer Ther. 2014 Feb;13(2):492-503. doi: 10.1158/1535-7163.MCT-13-0541. Epub 2013 Nov 5.

17.

Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.

Iusuf D, van Esch A, Hobbs M, Taylor M, Kenworthy KE, van de Steeg E, Wagenaar E, Schinkel AH.

Mol Pharmacol. 2013 May;83(5):919-29. doi: 10.1124/mol.112.081927. Epub 2013 Feb 19.

18.

Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.

van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2013 Feb 15;19(4):821-32. doi: 10.1158/1078-0432.CCR-12-2080. Epub 2012 Dec 14.

19.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2012 Sep 4;9(9):2497-504. doi: 10.1021/mp300108c. Epub 2012 Aug 3.

PMID:
22812517
20.

A wide variation in diagnostic and therapeutic strategies in chronic pancreatitis: a Dutch national survey.

van Esch AA, Ahmed Ali U, van Goor H, Bruno MJ, Drenth JP.

JOP. 2012 Jul 10;13(4):394-401. doi: 10.6092/1590-8577/676.

21.

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH.

J Clin Invest. 2012 Feb;122(2):519-28. doi: 10.1172/JCI59526. Epub 2012 Jan 9.

22.

Implementing RapidArc into clinical routine: a comprehensive program from machine QA to TPS validation and patient QA.

Van Esch A, Huyskens DP, Behrens CF, Samsoe E, Sjolin M, Bjelkengren U, Sjostrom D, Clermont C, Hambach L, Sergent F.

Med Phys. 2011 Sep;38(9):5146-66. doi: 10.1118/1.3622672.

PMID:
21978060
23.

Catechol-O-methyltransferase (COMT) gene variants and pain in chronic pancreatitis.

van Esch AA, de Vries E, Te Morsche RH, van Oijen MG, Jansen JB, Drenth JP.

Neth J Med. 2011 Jul-Aug;69(7):330-4.

24.

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH.

Drug Metab Dispos. 2011 Aug;39(8):1338-44. doi: 10.1124/dmd.111.038794. Epub 2011 May 12.

25.

High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.

van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2011 Jan 15;17(2):294-301. doi: 10.1158/1078-0432.CCR-10-1980. Epub 2010 Nov 19.

26.
27.

Polymorphisms in gene encoding TRPV1-receptor involved in pain perception are unrelated to chronic pancreatitis.

van Esch AA, Lamberts MP, te Morsche RH, van Oijen MG, Jansen JB, Drenth JP.

BMC Gastroenterol. 2009 Dec 24;9:97. doi: 10.1186/1471-230X-9-97.

28.

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, Schinkel AH.

Mol Cancer Ther. 2009 Dec;8(12):3350-9. doi: 10.1158/1535-7163.MCT-09-0668.

29.

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH.

Clin Cancer Res. 2009 May 1;15(9):3084-93. doi: 10.1158/1078-0432.CCR-08-2940. Epub 2009 Apr 21.

30.

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, Schinkel AH.

Clin Cancer Res. 2008 Dec 15;14(24):8152-60. doi: 10.1158/1078-0432.CCR-08-1609.

31.

Automatic segmentation of thoracic and pelvic CT images for radiotherapy planning using implicit anatomic knowledge and organ-specific segmentation strategies.

Haas B, Coradi T, Scholz M, Kunz P, Huber M, Oppitz U, André L, Lengkeek V, Huyskens D, van Esch A, Reddick R.

Phys Med Biol. 2008 Mar 21;53(6):1751-71. doi: 10.1088/0031-9155/53/6/017. Epub 2008 Mar 7.

PMID:
18367801
32.

On-line quality assurance of rotational radiotherapy treatment delivery by means of a 2D ion chamber array and the Octavius phantom.

Van Esch A, Clermont C, Devillers M, Iori M, Huyskens DP.

Med Phys. 2007 Oct;34(10):3825-37.

PMID:
17985628
33.

Recurrent idiopathic pancreatitis in familial adenomatous polyposis: report of a case-series and review of the literature.

van Esch AA, Drenth JP, te Morsche RH, Jansen JB, Nagengast FM.

Fam Cancer. 2007;6(3):275-80. Epub 2007 Feb 21. Review.

PMID:
17318339
34.

Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.

Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P.

Kidney Int. 2007 Apr;71(7):646-54. Epub 2007 Feb 14.

35.

The use of magnetic sensors to monitor moderate deep inspiration breath hold during breast irradiation with dynamic MLC compensators.

Remouchamps VM, Huyskens DP, Mertens I, Destine M, Van Esch A, Salamon E, De Neve W.

Radiother Oncol. 2007 Mar;82(3):341-8. Epub 2007 Jan 4.

PMID:
17207547
36.

Testing of the analytical anisotropic algorithm for photon dose calculation.

Van Esch A, Tillikainen L, Pyykkonen J, Tenhunen M, Helminen H, Siljamäki S, Alakuijala J, Paiusco M, Lori M, Huyskens DP.

Med Phys. 2006 Nov;33(11):4130-48.

PMID:
17153392
37.

Pharmacological management of pain in chronic pancreatitis.

van Esch AA, Wilder-Smith OH, Jansen JB, van Goor H, Drenth JP.

Dig Liver Dis. 2006 Jul;38(7):518-26. Epub 2006 Apr 14. Review.

PMID:
16627019
38.

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P.

Am J Pathol. 2005 Jul;167(1):47-58.

39.
40.

The use of an aSi-based EPID for routine absolute dosimetric pre-treatment verification of dynamic IMRT fields.

Van Esch A, Depuydt T, Huyskens DP.

Radiother Oncol. 2004 May;71(2):223-34.

PMID:
15110457
41.

Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity.

Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, Van Der Schaft DW, Van Esch AM, Joosten-Achjanie SR, Lambin P, Landuyt W, Griffioen AW.

Int J Cancer. 2003 May 20;105(1):20-5.

42.
43.

A quantitative evaluation of IMRT dose distributions: refinement and clinical assessment of the gamma evaluation.

Depuydt T, Van Esch A, Huyskens DP.

Radiother Oncol. 2002 Mar;62(3):309-19.

PMID:
12175562
44.
45.
46.

Quality assurance in radiotherapy by identifying standards and monitoring treatment preparation.

Van Esch A, Bogaerts R, Kutcher GJ, Huyskens D.

Radiother Oncol. 2000 Jul;56(1):109-15.

PMID:
10869761
47.

A method to estimate the transit dose on the beam axis for verification of dose delivery with portal images.

Bogaerts R, Van Esch A, Reymen R, Huyskens D.

Radiother Oncol. 2000 Jan;54(1):39-46.

PMID:
10719698
48.

Evaluation of an electronic portal imaging device for transit dosimetry.

He X, Van Esch A, Reymen R, Huyskens D.

Acta Oncol. 1999;38(5):591-6.

PMID:
10427947
49.

Prediction of febrile seizures in siblings: a practical approach.

van Esch A, Steyerberg EW, van Duijn CM, Offringa M, Derksen-Lubsen G, van Steensel-Moll HA.

Eur J Pediatr. 1998 Apr;157(4):340-4.

PMID:
9578974
50.

Outcome after febrile status epilepticus.

van Esch A, Ramlal IR, van Steensel-Moll HA, Steyerberg EW, Derksen-Lubsen G.

Dev Med Child Neurol. 1996 Jan;38(1):19-24.

PMID:
8606012

Supplemental Content

Loading ...
Support Center